Bing-Shu Li

Therapeutic targeting of the SLC39A13-AS1/TCF20/RUNX1 axis inhibits glutamine metabolism and ovarian cancer progression

“Glutamine addiction” is among the key features of tumor metabolic reprogramming and is an important target for tumor therapy. Unfortunately, the mechanisms underlying the abnormal expression of genes related to glutamine metabolism in ovarian cancer (OC) remain unclear. Here, we...